Write your message
Volume 7, Issue 6 (November - December 2022)                   J Obstet Gynecol Cancer Res 2022, 7(6): 524-529 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Boroumand F, Ghayur S, Gharaaghaji R, Vazifekhah S. Efficacy of Prophylactic Use of Metformin in Prevention of Gestational Diabetes Mellitus in Nondiabetic Obese Pregnant Women. J Obstet Gynecol Cancer Res. 2022; 7 (6) :524-529
URL: http://jogcr.com/article-1-583-en.html
1- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2- Department of Biostatistics and Epidemiology, Urmia University of Medical Sciences, Urmia, Iran
3- Department of Obstetrics and Gynecology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran , shabnamvazifekhah1985@gmail.com
Abstract:   (182 Views)

Background & Objective: Maternal obesity can increases pregnancy consequences like postpartum hemorrhage, preeclampsia, need for cesarean section, neonatal death, and fetal macrosomia. In this study, the efficacy of prophylactic use of metformin to prevent gestational diabetes mellitus in nondiabetic pregnant women with obesity was examined.
Materials & Methods: This study was a clinical trial. Totally, 340 pregnant women who were in the first trimester were referred to the gynecology clinic of Motahhari hospital in Urmia after ensuring the absence of underlying diseases such as diabetes, hypertension, kidney, liver, and cardiovascular disease, without a history of allergy to metformin, in case of a singleton pregnancy, and Body Mass Index (BMI) above 30 were allocated to two equal groups. The intervention group was given 1000 mg of metformin, and the control group was given a placebo. Demographic information, including age, gravity, parity, live birth, birth, and maternal weight, previous delivery method, abortion, delivery method with its cause, polyhydramnios, NICU hospitalization, gestational age, mortality, and neonatal anomalies was also recorded. The results were analyzed using SPSS version 26.
Results: In the control group, 15 mothers (9.4%) out of 160 people, and in the intervention group, 13 mothers (8.1%) had gestational diabetes (P=0.692). In the intervention group, the mean insulin dose was 10.8 ±3 units; in the control group, the mean insulin dose was 21.2±15.7 units (P=0.048). Twenty patients (6.7%) out of 297 obese patients and 8 patients (34.8%) in the morbid obesity group had diabetes (P<0.001). In the control group, the mean weight of mothers was 8.04±2.5 kg; in the intervention group, it was 5.2±2.3 kg during pregnancy (P<0.001). Gestational diabetes, delivery method, death one week after birth, preterm birth, polyhydramnios, and intensive care unit were similar in the two groups.
Conclusion: Metformin in pregnant women with a BMI>30 deals with low maternal weight, reduced birth weight, and reduced insulin dose in diabetic mothers.

     
Systematic Review: Original Research | Subject: Obstetrics and Gynecology
Received: 2021/12/25 | Accepted: 2022/04/18 | Published: 2022/09/9

References
1. Sales WB, Nascimento IBd, Dienstmann G, Souza MLRd, Silva GDd, Silva JC. Effectiveness of metformin in the prevention of gestational diabetes mellitus in obese pregnant women. Rev Bras de Ginecol e Obstet. 2018;40:180-7. [DOI:10.1055/s-0038-1642632] [PMID]
2. Elmaraezy A, Ibrahim Abushouk A, Emara A, Elshahat O, Ahmed H, I. Mostafa M. Effect of metformin on maternal and neonatal outcomes in pregnant obese non-diabetic women: A meta-analysis. Int J Reprod Biomed. 2017;15(8):461-70. [DOI:10.29252/ijrm.15.8.461] [PMID] [PMCID]
3. Chiswick C, Reynolds RM, Denison F, Drake AJ, Forbes S, Newby DE, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778-86. [DOI:10.1016/S2213-8587(15)00219-3]
4. Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore T, Greene MF. Creasy and Resnik's Maternal-Fetal Medicine: Principles and Practice E-Book: Expert Consult Premium Edition-Enhanced Online Features: Elsevier Health Sciences; 2013.
5. Su DF, Wang XY. Metformin vs insulin in the management of gestational diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2014;104(3):353-7. [DOI:10.1016/j.diabres.2013.12.056] [PMID]
6. Dodd JM, Grivell RM, Deussen AR, Hague WM. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. Cochrane Database Syst Rev. 2018(7). [DOI:10.1002/14651858.CD010564.pub2] [PMID]
7. Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-76. [DOI:10.1007/s00125-017-4318-z] [PMID]
8. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-85. [DOI:10.1007/s00125-017-4342-z] [PMID] [PMCID]
9. Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926-7. [DOI:10.1001/jama.2019.3805] [PMID] [PMCID]
10. Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. j Isfahan Univ Med Scienc. 2014;19(7):658. [DOI:10.12659/MSMBR.889344] [PMID] [PMCID]
11. Rezaei Z, Valadan M, Shojaee Asl P. The Effect of Laparoscopic Ovarian Electrocautery in Pregnancy Rate in Metformin-and Clomiphene Citrate-Resistant Infertile Women. J Obstet Gynecol Cancer Res. 2020;5(3):84-7. [DOI:10.30699/jogcr.5.3.84]
12. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk: Lippincott Williams & Wilkins; 2012.
13. Abdali F, Taghavi S, Vazifekhah S, Behzad MN, Attari MMA. Effect of progesterone on latent phase prolongation in patients with preterm premature rupture of membranes. Acta Med Iran. 2017:772-8.
14. Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med. 2016;374(5):434-43. [DOI:10.1056/NEJMoa1509819] [PMID]
15. Pedersen J. Diabetes and pregnancy; blood sugar of newborn infants during fasting and glucose administration. Ugeskr Laeg. 1952;114(21):685.
16. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003-15. [DOI:10.1056/NEJMoa0707193] [PMID]
17. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU) body composition at 2 years of age. Diabetes Care. 2011;34(10):2279-84. [DOI:10.2337/dc11-0660] [PMID] [PMCID]
18. Bettencourt-Silva R, Neves JS, Ferreira MJ, Souteiro P, Belo S, Oliveira AI, et al. Metformin in overweight and obese women with gestational diabetes: a propensity score-matched study. Endocrine. 2019;66(2):192-200. [DOI:10.1007/s12020-019-02043-3] [PMID]
19. Abd El Fattah EA. Can metformin limit weight gain in the obese with pregnancy? Int J Reprod Contracept Obstet Gynecol. 2016;5(3):818-26. [DOI:10.18203/2320-1770.ijrcog20160591]
20. Dodd JM, Louise J, Deussen AR, Grivell RM, Dekker G, McPhee AJ, et al. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(1):15-24. [DOI:10.1016/S2213-8587(18)30310-3]
21. Vanky E, Stridsklev S, Heimstad R, Romundstad Pl, Skogøy K, Kleggetveit O, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448-E55. [DOI:10.1210/jc.2010-0853] [PMID]
22. Hyer S, Balani J, Shehata H. Metformin in pregnancy: mechanisms and clinical applications. Int J Mol Sci. 2018;19(7):1954. [DOI:10.3390/ijms19071954] [PMID] [PMCID]
23. Pascual-Morena C, Cavero-Redondo I, Álvarez-Bueno C, Lucerón-Lucas-Torres M, Sanabria-Martínez G, Poyatos-León R, et al. Exercise versus metformin to improve pregnancy outcomes among overweight pregnant women: a systematic review and network meta-analysis. J Clin Med. 2021;10(16):3490. [DOI:10.3390/jcm10163490] [PMID] [PMCID]
24. Christianson MS, Wu H, Zhao Y, Yemini M, Leong M, Shoham Z. Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey. J Assist Reprod Genet. 2015;32(3):401-6. [DOI:10.1007/s10815-014-0414-x] [PMID] [PMCID]
25. Ghajari H, Nouhjah S, Shahbazian H, Valizadeh R, Tahery N. Postpartum glucose testing, related factors and progression to abnormal glucose tolerance in a rural population with a known history of gestational diabetes. Diabetes Metab Synd: Clin Res Rev. 2017;11:S455-S8. [DOI:10.1016/j.dsx.2017.03.035] [PMID]
26. Sepahi MA, Lakkakula BVKS, Kellner SJ, Valizadeh R. Administration of metformin in type 2 diabetes mellitus patients with chronic kidney disease; facts and myths. J Nephropathol. 2020;9(1):1-6. [DOI:10.15171/jnp.2020.04]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2022 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.